Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

24 August 2020: Lab/In Vitro Research

Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells

Jiansheng Zhong 1ABE* , Jinli Zhang 2AB , Xiaoyang Yu 3BF , Xing Zhang 1CD , Linping Dian 1CD

DOI: 10.12659/MSM.924922

Med Sci Monit 2020; 26:e924922

Table 1 Effect of olmutinib on enhancement of doxorubicin.

CompoundIC50 (μM) (fold-reversal)
K562 Oe-NCK562 Oe-ETS1K562/ADR Oe-NCK562/ADR Oe-ETS1
Dox0.143±0.008 (1.00)0.197±0.009 (1.00)0.202±0.009 (1.00)2.432±0.131 (1.00)***
+Olm 0.25 μM0.136±0.018 (1.04)0.183±0.009 (1.07)0.184±0.01 (1.11)1.331±0.123 (1.71)***
+Olm 0.5 μM0.113±0.016 (1.22)0.168±0.097 (1.18)0.153±0.031 (1.21)0.501±0.107 (4.66)***
+Olm 1 μM0.061±0.009 (1.84)0.114±0.024 (1.73)0.109±0.063 (1.42)0.233±0.054 (10.08)***
The fold-reversal of MDR (values given in parentheses) was calculate as described in Material and Methods. Data are shown as the mean±standard deviation (SD) of 3 independent experiments.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750